GlassScriptPhysician profile
Tracy D Southern
NPI 1740726660
$4,609.37
in general payments reported to CMS, 2019-2025
34 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.55 · 2022: $57.50 · 2023: $1,410 · 2024: $1,598 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,473.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $783.64 | 2023-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $370.30 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $362.41 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $240.22 | 2023-2025 | |
| Lilly USA, LLC | $215.12 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $203.42 | 2023-2024 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.47 | 2021-2025 | Jardiance |
| Amgen INC. | $145.78 | 2023-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $140.66 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $117.61 | 2023-2025 | |
| Exact Sciences Corporation | $113.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.61 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $67.92 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $66.44 | 2024-2025 | Gemtesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.77 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $60.80 | 2024-2025 | Heplisav-B |
| Axsome Therapeutics, INC. | $50.06 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $50.05 | 2024-2025 | Veozah |
| Ironwood Pharmaceuticals, INC | $49.40 | 2023-2024 | Linzess |
| Globus Medical, INC. | $43.10 | 2025 | Senza |
| Boston Scientific Corporation | $39.58 | 2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $37.76 | 2025 | |
| Idorsia Pharmaceuticals US INC | $37.68 | 2023-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $34.15 | 2024 | Zoryve |
| Protega Pharmaceutials INC | $32.39 | 2025 | Roxybond |
| Tersera Therapeutics LLC | $28.22 | 2025 | Zoladex |
| Tempus Ai, INC | $21.08 | 2024 | |
| Lundbeck LLC | $20.03 | 2023 | Rexulti |
| Dexcom, INC. | $17.85 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $17.57 | 2023 | |
| Organon LLC | $16.23 | 2024 | |
| Masimo Corporation | $14.48 | 2022 | |
| Mylan Specialty L.P. | $14.05 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Southern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.